Showing 91-95 of 259 resources:
RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

Dermatology Times Mar 19, 2023 Kaitlyn Bader Read the Full Article >>   A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA. There is a lack of evidence investigating the impact of patient-reported outcomes (PROs) monitoring in routine clinical practice, according to a[…]

Interview with OM1’s Jessica Paulus at SCOPE

Published on: March 9, 2023 Applied Clinical Trials Watch the Full Interview >> Key Learning Objectives: Challenges people encounter when working with RWD How can RWD help address gaps in care? How OM1 engages or supports health equity research using RWD

Hard to Define, Harder to Find Patients: Using AI & Real-World Data to Understand Treatment Resistant Depression

Read the latest blog featuring Drs. Carl Marci & Joseph Zabinski in tHEORetically Speaking Written by: Undine McEvoy March 13, 2023 Mental health conditions can take a staggering toll on an individual physically, socially and financially. Many patients languish with partially effective or ineffective treatments, even though new options are constantly entering the market. At[…]

Using Real-World Data & AI to Phenotype HFpEF Patients & Advance Heart Failure Research

Webinar Date: Tuesday, March 28th from 2:00-3:00pm ET Presented by Dr. Gary Curhan, CMO Register here Recent studies have shown that HFpEF comprises half of all heart failure cases. The prevalence of HFpEF has increased over the last 2 decades, associated with an aging population and increasing prevalence of risk factors, such as hypertension and[…]

Using Real-World Data & AI to Phenotype HFpEF Patients & Advance Heart Failure Research

Recent studies have shown that HFpEF comprises half of all heart failure cases. The prevalence of HFpEF has increased over the last 2 decades, associated with an aging population and increasing prevalence of risk factors, such as hypertension and diabetes mellitus. Yet, trials of conventional heart failure medications have been inconclusive in HFpEF and to[…]